Ul­tragenyx, Mereo’s bone dis­ease drug fails sec­ond in­ter­im analy­sis, stocks plum­met

Ul­tragenyx Phar­ma­ceu­ti­cal and Mereo Bio­Phar­ma’s an­ti­body for a rare bone dis­ease failed a sec­ond in­ter­im analy­sis in its piv­otal tri­al, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.